Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | VP, Corporate Controller | June 13, 2022 | June 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,447 |
Reported balance
After 2022-06-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-13 · Sale · Disposed 42 · Balance 4,447 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This number includes unvested RSUs previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This number includes unvested RSUs previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2022 Filed Jun 15, 2022 20:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 42 | $62.60 | $2,629.20 |
DisclosureSEC source: 0001127602-22-017544 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 249 | $62.69 | $15,609.81 |
DisclosureSEC source: 0001127602-22-016885 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,489 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 134 | $59.10 | $7,919.40 |
DisclosureSEC source: 0001127602-22-015364 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,738 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 2,029 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-22-014976 · form4.xml · derivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,029 Underlying: Common Stock · 2,029 shares Expires 2029-05-16 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 868 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014976 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,872 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 50 | $56.10 | $2,805.00 |
DisclosureSEC source: 0001127602-22-014976 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 39 | $59.87 | $2,334.93 |
DisclosureSEC source: 0001127602-21-020056 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,054 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 81 | $55.09 | $4,462.29 |
DisclosureSEC source: 0001127602-21-019529 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,093 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:42 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-018998 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,174 F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant. F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:08 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 42 | $55.19 | $2,317.98 |
DisclosureSEC source: 0001127602-21-017683 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,421 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:08 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 2,690 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-21-017683 · form4.xml · derivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690 Underlying: Common Stock · 2,690 shares Expires 2028-05-18 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:08 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-017683 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,463 F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2021 Filed May 18, 2021 22:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 42 | $55.97 | $2,350.74 |
DisclosureSEC source: 0001127602-21-017273 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $98.03 | $0.00 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · derivative · entry 10 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,503 Underlying: Common Stock · 500 shares Expires 2026-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 476 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · derivative · entry 9 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 952 Underlying: Common Stock · 476 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,457 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · derivative · entry 8 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,457 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 238 | $136.26 | $32,429.88 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 7 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,511 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 500 | $135.72 | $67,860.00 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 6 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 500 | $98.03 | $49,012.50 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 476 | $135.88 | $64,678.88 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 476 | $93.52 | $44,515.52 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,457 | $135.84 | $197,918.88 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,457 | $34.21 | $49,843.97 |
DisclosureSEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 21:02 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $106.00 | $10,600.00 |
DisclosureSEC source: 0001127602-20-027621 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 3,040 | $91.53 | $278,251.20 |
DisclosureSEC source: 0001127602-20-019789 · form4.xml · nonDerivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,849 F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,282 | $87.71 | $112,444.22 |
DisclosureSEC source: 0001127602-20-019789 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,889 F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 92 | $87.16 | $8,018.72 |
DisclosureSEC source: 0001127602-20-019789 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,171 F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 42 | $82.29 | $3,456.18 |
DisclosureSEC source: 0001127602-20-019789 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,263 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019789 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,305 F1 · kind: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020. F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 187 | $97.19 | $18,174.53 |
DisclosureSEC source: 0001127602-20-019382 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,106 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-20-019382 · form4.xml · derivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107 Underlying: Common Stock · 1,106 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,106 | $99.09 | $109,593.54 |
DisclosureSEC source: 0001127602-20-019382 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,170 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,106 | $41.64 | $46,053.84 |
DisclosureSEC source: 0001127602-20-019382 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 83 | $97.03 | $8,053.49 |
DisclosureSEC source: 0001127602-20-019382 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,170 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,841 | $0.00 Strike: $103.37 | $0.00 |
DisclosureSEC source: 0001127602-20-017278 · form4.xml · derivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,841 Underlying: Common Stock · 1,841 shares Expires 2027-05-18 F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-017278 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,253 F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F5 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2020 Filed May 19, 2020 22:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 101 | $101.72 | $10,273.72 |
DisclosureSEC source: 0001127602-20-017278 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,709 F3 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 42 | $100.44 | $4,218.48 |
DisclosureSEC source: 0001127602-20-017278 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,810 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| April 08, 2020 Filed Apr 8, 2020 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 399 | $97.12 | $38,750.88 |
DisclosureSEC source: 0001127602-20-013507 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,852 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 201 | $103.91 | $20,885.91 |
DisclosureSEC source: 0001127602-20-013507 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,251 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,607 | $0.00 Strike: $34.42 | $0.00 |
DisclosureSEC source: 0001127602-20-013507 · form4.xml · derivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,607 shares Expires 2023-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,607 | $101.62 | $264,923.34 |
DisclosureSEC source: 0001127602-20-013507 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,452 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,607 | $34.42 | $89,732.94 |
DisclosureSEC source: 0001127602-20-013507 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 00:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 237 | $122.69 | $29,077.53 |
DisclosureSEC source: 0000899243-19-026148 · doc4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,452 F1 · kind: Transaction pursuant to an existing 10b5-1. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 00:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $120.33 | $12,033.00 |
DisclosureSEC source: 0000899243-19-026148 · doc4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,456 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0000899243-19-026148 · doc4.xml · derivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,457 Underlying: Common Stock · 1,456 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,456 | $120.32 | $175,185.92 |
DisclosureSEC source: 0000899243-19-026148 · doc4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,789 F1 · kind: Transaction pursuant to an existing 10b5-1. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,456 | $34.21 | $49,809.76 |
DisclosureSEC source: 0000899243-19-026148 · doc4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 475 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-19-026402 · form4.xml · derivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 475 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 475 | $133.23 | $63,284.25 |
DisclosureSEC source: 0001127602-19-026402 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,789 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.